Arkolith/Insider Trading/XFOR/Form 4

DiBiase Mary

Chief Operating OfficerX4 Pharmaceuticals, Inc (XFOR) · full profile →Form 4 · filed Oct 8, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$39K
Net Open-Market Flow
-$39K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 7, 2024Sell(S)68K$0.57$39K452K
Oct 4, 2024Grant(A)231K—$0520K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-24-042542) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML